KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.

Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Haibo Wang, Yongmei Yin, Xiaojia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shusen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yiding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yueyin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan

Nat Med 30(1) 249-256

PMID38191615
PMCID-
DOI10.1038/s41591-023-02677-x
发表日期2024-01-08
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated mixed results. TORCHLIGHT is a randomized, double-blinded phase 3 trial evaluating the efficacy and safety of first-line toripalimab and nab-paclitaxel (nab-P) (n = 353; experimental arm) versus placebo and nab-P (n = 178; control arm) for the treatment of women with metastatic or recurrent TNBC. The primary end point was progression-free survival (PFS) assessed by a blinded independent central review in the PD-L1-positive and intention-to-treat populations. The secondary end points included overall survival and safety. Overall, 200 and 100 patients, in the toripalimab and placebo arm respectively had PD-L1-positive TNBC. At the prespecified interim analysis, a statistically significant improvement in PFS assessed by a blinded independent central review was demonstrated in the experimental arm in the PD-L1-positive population (median PFS 8.4 versus 5.6 months; hazard ratio (HR) = 0.65, 95% confidence interval (CI) 0.470-0.906, P = 0.0102). The median overall survival was 32.8 versus 19.5 months (HR = 0.62, 95% CI 0.414-0.914, P = 0.0148). Similar incidences of treatment-emergent adverse events (AEs) (99.2% versus 98.9%), grade ≥3 treatment-emergent AEs (56.4% versus 54.3%) and fatal AEs (0.6% versus 3.4%) occurred in the experimental and control arms. The addition of toripalimab to nab-P provided a significant improvement in PFS for PD-L1-positive patients with metastatic or recurrent TNBC with an acceptable safety profile. ClinicalTrial.gov identifier NCT03777579 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。